From: Brou, Kelly [KBrou@joneswalker.com]

**Sent**: 5/17/2018 4:56:41 PM

To: Orme-Zavaleta, Jennifer [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=3c5a111dc377411595e5b24b5d96146b-Orme-Zavaleta, Jennifer]; Gentry,

Nathan [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=a8f7a2857a234d06b785cc36c73fdddd-Gentry, Nathan]; Bahadori, Tina

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=7da7967dcafb4c5bbc39c666fee31ec3-Bahadori, Tina]; Fine, Steven

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=d28c9693c45c41e8a941bc51d2c4914c-Fine, Steve]; Gray, David

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=881c62b1e54142388c1de2f8e3799c33-Gray, David]; Holloman, Vincia

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=e7e9f8511bc84976ae1eae93e17062fa-Holloma, Vincia]; Idsal, Anne

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=b1beca8121fb47a08e82b6bf2247a79b-Idsal, Anne]; Thayer, Kris

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=3ce4ae3f107749c6815f243260df98c3-Thayer, Kri]; Vandenberg, John

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=dcae2b98a04540fb8d099f9d4dead690-Vandenberg, John]; Yamada, Richard

(Yujiro) [/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=4c34a1e0345e4d26b361b5031430639d-Yamada, Yuj]; Dravis, Samantha

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=ece53f0610054e669d9dffe0b3a842df-Dravis, Sam]; Quality

[/o=ExchangeLabs/ou=Exchange Administrative Group

(FYDIBOHF23SPDLT)/cn=Recipients/cn=09879eff255940b8951dc434052ea44f-Quality]

CC: Jorge-Lavastida@denka-pe.com; Holden, Bob [BHolden@joneswalker.com]; Henry, Elise [EHenry@joneswalker.com]

Subject: Chloroprene RFC #17002 (Status Rpt on PBPK Model)

Attachments: Orme-Zavaleta 05-17-18 (re PBPK Model) (N3597825x7A3A0).pdf

## This is being emailed on behalf of Mr. Holden

## Dear Sir or Madam:

Attached please find correspondence regarding the chloroprene PBPK model. We would very much appreciate a prompt written response to this correspondence by email or other correspondence. Thank you for your attention to this.



**Celly Brou** 

Legal Secretary to Robert Holden, Christoffer Friend, Meghan E. Smith and Elise Henry

Jones Walker LLP

D: 504.582.8629 F: 504.589.8629

kbrou@joneswalker.com

201 St. Charles Ave, Ste 5100 New Orleans, LA 70170 T: 504.582.8000 www.joneswalker.com